003000.KS
Bukwang Pharmaceutical Co., Ltd.
KSC · Healthcare · Drug Manufacturers - Specialty & Generic · KR
KRW 3,700.00
−1.33%Year over year
Reported trailing growth
- Revenue
- +22.2%
- EBITDA
- +9.5%
- EBIT
- +61.2%
- EPS
- -55.8%
- Free cash flow
- -21.5%
- Operating cash flow
- -18.1%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +1.7%
- EBITDA
- +59.0%
- EBIT
- +775.2%
- Net income
- +576.0%
- EPS
- +493.9%
- Free cash flow
- -0.9%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2026